Clinical Trial Update: A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for two GlaxoSmithKline compounds (GW597599 and GR205171) investigating treatment for primary insomnia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• GR205171
• GW597599

Snippet

Sponsor: GlaxoSmithKline | Conditions: Sleep Initiation and Maintenance Disorders | Phase 2 | Status: COMPLETED